Moderna, Merck's Personalized Cancer Vaccine Shows Promise.

Moderna and Merck said Wednesday their personalized cancer vaccine met key goals in its first large, late-stage trial. The treatment reduced both melanoma recurrence and distant spread compared with Keytruda alone.

• 1,137 high-risk patients with surgically removed stage IIB-IV melanoma enrolled in the trial.
• 49% reduction in recurrence risk was reported in earlier Phase 2 data after five years.
• Moderna shares rose as much as 106% in premarket trading; Merck climbed roughly 7%.
• Analysts estimate the approved product could generate more than $6 billion in annual melanoma sales.

Why it matters: The trial is the first Phase 3 study to validate personalized cancer vaccines, a concept researchers have pursued for over a century. Success opens a potential path to treating lung, bladder, and kidney cancers with the same approach.

• Each vaccine is built from genetic sequencing of a patient's own tumor, targeting mutations unique to that individual rather than applying a single formula.
• Melanoma causes the large majority of skin-cancer deaths despite representing only about 1% of skin cancer cases.

How 59 sources split on this story

Where they split: The companies have not released detailed trial data or published results in a peer-reviewed journal, leaving independent verification pending.

What’s next: Full results will be presented at an international medical meeting, date not yet set.

• Moderna's president said an FDA filing is expected in months, not years.
• Whether the treatment extends overall survival remains unanswered; the trial continues.
• Will full data, once published, confirm the interim results reported in the press release?
• Does the combination extend overall survival, or only delay recurrence?
• Can the personalized manufacturing process scale quickly enough for broad commercial use?